[
    {
        "molecule_name": "IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<∼1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": ">∼1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<∼1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": ">∼1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits high affinity binding to FcRn at pH 6.0 characterized by a KD of less than about 500 nM.\nIn one embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, for example, the molecule of the invention can include an IgG constant domain, or FcRn-binding fragment thereof, that exhibits binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM.\nIn one embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of less than ∼1000 nM.\nIn another embodiment, the molecule of the invention includes an IgG constant domain, or FcRn-binding fragment thereof, such as an Fc region or hinge-Fc region, that exhibits binding affinity to FcRn at pH 6.0 characterized by a KD of less than about 500 nM, and a binding affinity to FcRn at pH 7.4 characterized by a KD of more than ∼1000 nM but less than the KD of a comparable wild-type molecule at pH 7.4."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<200",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<300",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<400",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "10",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "50",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "50",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "1",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "5",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "10",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "20",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "30",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "40",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "50",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "<1",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "50",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "200",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "800",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "1000",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "50",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "400",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "500",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Immunoglobulin G",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": ">1",
        "unit": "µM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In some embodiments, modified IgGs and other molecules of the invention contain a modified IgG constant domain or FcRn-binding fragment thereof (e.g., an Fc region or hinge-Fc region), that exhibits a KD for binding to FcRn at pH 6.0 of less than 100nM, less than 200 nM, less than 300nM, less than 400 nM, less than 500nM or less than 1000nM.\n* Modified IgGs of the invention can, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 nM.\n* Additionally or alternatively, a modified IgG can exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 µM.\n* Without intending to be bound by theory, it is observed that a threshold may exist: at pH 7.4, a KD of about 1µM or higher (e.g., a KD of 1µM, 5µM 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, or higher; that is, binding affinities in the micromolar or millimolar range evidencing lower binding affinity for FcRn) may be associated with a modified IgG or other molecule having enhanced half-life (slower clearance), while a KD of less than 1 µM at pH 7.4 (e.g., a KD of 50 nM, 100nM, 200nM, 500nM, 800nM up to about 1000nM; that is, binding affinities in the nanomolar range, evidencing higher binding affinity for FcRn) may be associated with a modified IgG or other molecule having a shortened half-life (faster clearance).\n* An increased half-life for the modified IgG or other molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM to 400 nM or 500 nM for binding at pH 6, and a KD of more than 1µM at pH 7.4.\n* The YTE mutant has enhanced binding affinity for FcRn at pH 6.0 and relatively low binding affinity at 7.4, and exhibits a 3-4 fold increase in in vivo half-life and clearance, compared to a wild-type IgG constant domain."
    },
    {
        "molecule_name": "Motavizumab",
        "protein_target_name": "FcRn",
        "binding_metric": "KD",
        "value": "25",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Tight binding to FcRn at pH 7.4 (e.g., KD of 25 nM) for N3E-YTE was associated with fast serum clearance rates.\nHowever, as the KD at pH 7.4 decreased below 1 uM at pH 7.4, the IgG began to exhibit enhanced half-life and slower clearance rates."
    }
]